Videos

Loretta Nastoupil, MD, and John Burke, MD, review data from the L-MIND study presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

An overview of CD19 as a treatment target for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Insight into the combination of tafasitamab plus lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Stephanie Lee, MD, MPH, discusses the study of ruxolitinib plus best available therapy as a second-line treatment for patients with chronic graft-versus-host disease.

Bijal Shah, MD, MS, discusses the results of treatment with the chimeric antigen receptor T-cell therapy brexucabtagne autoleucel in the ZUMA-3 trial in patients with acute lymphoblastic leukemia.

Justine Kahn, MD, MS, discusses the Children’s Oncology Group study that identified a survival disparity among patients with de novo Hodgkin lymphoma of different races and economic statuses.

Kamran A. Ahmed, MD, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab and pertuzumab in the management of HER2-positive breast leptomeningeal disease.

Gilles Salles, MD, discusses the need for new therapies to treat diffuse large B-cell lymphoma.

Implications for using checkpoint inhibitors as neoadjuvant treatment for patients with advanced urothelial carcinoma based on clinical trial data.

Preferences for treating patients with locally advanced urothelial carcinoma based on various factors, including disease presentation and patient preference.

Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer. 

Loretta Nastoupil, MD, and John Burke, MD, discuss transplant as a treatment option for patients with relapsed/refractory [R/R] diffuse large B-cell lymphoma [DLBCL], as well as treatment options for patients with relapsed disease after transplant.

Loretta Nastoupil, MD, and John Burke, MD, provide insight into treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Loretta Nastoupil, MD, and John Burke, MD, provide an overview of different prognostic factors that have been identified in diffuse large B-cell lymphoma (DLBCL).

John Mascarenhas, MD, and Ruben Mesa, MD, provide insight on the diagnosis and prognosis of myelofibrosis.

Loretta Nastoupil, MD, and John Burke, MD, discuss the therapeutic landscape for patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and begin with an overview of the disease.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.

A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.

Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.

A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.

A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.

A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC. 

Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.

Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.

The doctors discuss new discoveries that may lead to a cure for MPNs.

Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.